Type to search

Search News is My Business

The project will transform Lilly del Caribe’s PR01 plant, built in 1968, into an oral solid dose manufacturing facility for orforglipron — Lilly’s first oral GLP-1 receptor agonist — while expanding the PR05 plant dedicated to insulin production.

Uh-oh! It looks like you're using an ad blocker.

Our website relies on ads to provide free content and sustain our operations. By turning off your ad blocker, you help support us and ensure we can continue offering valuable content without any cost to you.

We truly appreciate your understanding and support. Thank you for considering disabling your ad blocker for this website